Osteoarthritis - 2001 National Meeting Reports (cont.)
Merck withdrew Vioxx from the market after the data safety monitoring board overseeing a long-term study of the drug recommended that the study be halted because of an increased risk of serious cardiovascular events, including heart attacks and strokes, among study patients taking Vioxx compared to patients receiving placebo. The study was being done in patients at risk of developing recurrent colon polyps.
Rates of swelling of the tissues (edema) and
elevated blood pressure were reported as being significantly elevated in
patients taking Vioxx in comparison with patients taking Celebrex. Although
another study comparing rates of edema and high blood pressure to Naproxen
showed no difference.
Quadriceps muscle (the muscle in the front of the
thigh) weakness and obesity were related to an increase in the development of
knee osteoarthritis with pain symptoms.
In a study of total knee replacement in patients
with severe osteoarthritis of this joint, it was demonstrated that the patient's
overall sense of body pain and physical function significantly improved.
For more, please see MedicineNet.com' s Osteoarthritis article.
Last Editorial Review: 7/6/2004